Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Schechter Investment Advisors LLC

Schechter Investment Advisors LLC cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 15.9% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 719 shares of the biopharmaceutical company’s stock after selling 136 shares during the period. Schechter Investment Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $456,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the business. Arizona State Retirement System increased its position in shares of Regeneron Pharmaceuticals by 1.5% during the first quarter. Arizona State Retirement System now owns 31,684 shares of the biopharmaceutical company’s stock worth $20,095,000 after purchasing an additional 460 shares in the last quarter. Ballentine Partners LLC increased its position in shares of Regeneron Pharmaceuticals by 10.1% in the 1st quarter. Ballentine Partners LLC now owns 1,010 shares of the biopharmaceutical company’s stock valued at $641,000 after acquiring an additional 93 shares during the period. B & T Capital Management DBA Alpha Capital Management increased its position in shares of Regeneron Pharmaceuticals by 11.5% in the 1st quarter. B & T Capital Management DBA Alpha Capital Management now owns 3,510 shares of the biopharmaceutical company’s stock valued at $2,226,000 after acquiring an additional 363 shares during the period. Callahan Advisors LLC increased its position in shares of Regeneron Pharmaceuticals by 8.0% in the 1st quarter. Callahan Advisors LLC now owns 935 shares of the biopharmaceutical company’s stock valued at $593,000 after acquiring an additional 69 shares during the period. Finally, Park Square Financial Group LLC increased its position in shares of Regeneron Pharmaceuticals by 266.7% in the 1st quarter. Park Square Financial Group LLC now owns 286 shares of the biopharmaceutical company’s stock valued at $181,000 after acquiring an additional 208 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

REGN has been the topic of several research reports. Robert W. Baird cut their target price on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating on the stock in a research report on Friday, April 25th. Bank of America cut their target price on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating on the stock in a research report on Thursday, April 17th. Royal Bank Of Canada downgraded Regeneron Pharmaceuticals from a “moderate buy” rating to a “hold” rating and set a $662.00 target price on the stock. in a research report on Friday, May 30th. The Goldman Sachs Group cut their target price on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating on the stock in a research report on Wednesday, April 30th. Finally, Wall Street Zen downgraded Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $823.54.

Regeneron Pharmaceuticals Trading Down 4.0%

REGN stock opened at $547.96 on Wednesday. The company’s 50-day simple moving average is $544.35 and its 200-day simple moving average is $617.69. The company has a quick ratio of 4.03, a current ratio of 4.93 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,211.20. The firm has a market cap of $59.16 billion, a P/E ratio of 13.95, a PEG ratio of 2.11 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The firm had revenue of $3.03 billion for the quarter, compared to analysts’ expectations of $3.40 billion. During the same period in the previous year, the company earned $9.55 earnings per share. The company’s revenue was down 3.7% compared to the same quarter last year. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.64%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.